EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Implications for methenamine hippurate use in recurrent urinary tract infection management: Formaldehyde resistance and altered urinary composition

Niamh C Hodgkinson, Tabarak Al-Rubaye, Thomas C P Reed, Catherine Mowbray, Daniel Sarkissian, Louise Cowley, Frank Sargent, Judith Hall, Priyanka Krishnaswamy, Chris Harding, Phillip D Aldridge iD

PLOS Pathogens · 24.03.2026 · 22 (3) · e1014081

DOI: 10.1371/journal.ppat.1014081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 24.03.2026. Verfasst von Niamh C Hodgkinson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom. Hauptthemen laut MEDLINE: Formaldehyde, Methenamine, Urinary Tract Infections, Hippurates. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health and Care Research, Wellcome Trust, Biotechnology and Biological Sciences Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methenamine is a urinary antiseptic used to prevent urinary tract infections (UTI) via conversion to formaldehyde in the urinary tract. Methenamine hippurate (MH) is non-inferior compared to antibiotic (ABX) prophylaxis to manage recurrent UTI (rUTI) as demonstrated in the clinical trial ALTAR. Treatments such as MH, can improve antibiotic stewardship, as the primary treatment option for UTI is antibiotics. However, MH exhibits an elevated incidence risk with respect to breakthrough UTI as defined during ALTAR. Formaldehyde is highly toxic, while also a common byproduct of cellular metabolism. Powerful detoxification pathways exist to overcome formaldehyde toxicity. One example is the thiol-dependent metabolism of formaldehyde to formate in bacteria. The urinalysis of ALTAR urines detected formaldehyde in 85% of participant urines who were taking MH. HPLC analysis of a subset of urines from MH and ABX ALTAR participants, determined a significant change in urine composition. This included elevated levels of formate in urines from MH users. The thiol-dependant formaldehyde detoxification system of Escherichia coli is encoded by the frmRAB operon. The genes frmAB encode the enzymes responsible for detoxification, while frmR encodes a repressor of the system. ALTAR derived E. coli isolates were screened for growth in the presence of formaldehyde with 5.8% able to grow in > 1 mM formaldehyde. Bioinformatics identified 4 frmR alleles encoding non-functional FrmR variants and two plasmid-encoded frmA homologues. Growth in artificial urine confirmed that E. coli was susceptible to methenamine-formaldehyde conversion at pH6.0 and 5.6. All strains encoding frmR alleles grew in the presence of > 1 mg/ml methenamine at pH 5.6. The identification of FDH R in a clinical context and the changes in urine composition can improve the managed use of MH. However, a mindset change is needed to accept that MH, like antibiotics, has its own associated risks, including bacterial resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FormaldehydeMethenamineUrinary Tract InfectionsHippuratesAnti-Infective Agents, UrinaryEscherichia coli InfectionsHumansEscherichia coliAnti-Bacterial AgentsFemaleDrug Resistance, Bacterial

Substanzen

FormaldehydeMethenaminemethenamine hippurateHippuratesAnti-Infective Agents, UrinaryAnti-Bacterial Agents

Autor:innen und Institutionen

  • Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • School of Biomedical Sciences, Nutrition and Sport Sciences, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Gynaecology and Women's services, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.
  • Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Urology Department, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom.

ORCID-Profile: Phillip D Aldridge

Förderung

  • National Institute for Health and Care Research
  • Wellcome Trust
  • Biotechnology and Biological Sciences Research Council
  • The Urology Foundation
  • Microbiology Society

Zitieren

APA

Hodgkinson, N. C., Al-Rubaye, T., Reed, T. C. P., Mowbray, C., Sarkissian, D., Cowley, L., Sargent, F., Hall, J., Krishnaswamy, P., Harding, C., & Aldridge, P. D. (2026). Implications for methenamine hippurate use in recurrent urinary tract infection management: Formaldehyde resistance and altered urinary composition. PLOS Pathogens, 22(3), e1014081. https://doi.org/10.1371/journal.ppat.1014081

Vancouver

Hodgkinson NC, Al-Rubaye T, Reed TCP, Mowbray C, Sarkissian D, Cowley L, et al. Implications for methenamine hippurate use in recurrent urinary tract infection management: Formaldehyde resistance and altered urinary composition. PLOS Pathogens. 2026;22(3):e1014081. doi:10.1371/journal.ppat.1014081

BibTeX
@article{Hodgkinson2026,
  author = {Hodgkinson, Niamh C and Al-Rubaye, Tabarak and Reed, Thomas C P and Mowbray, Catherine and Sarkissian, Daniel and Cowley, Louise and Sargent, Frank and Hall, Judith and Krishnaswamy, Priyanka and Harding, Chris and Aldridge, Phillip D},
  title = {Implications for methenamine hippurate use in recurrent urinary tract infection management: Formaldehyde resistance and altered urinary composition},
  journal = {PLOS Pathogens},
  year = {2026},
  volume = {22},
  number = {3},
  pages = {e1014081},
  doi = {10.1371/journal.ppat.1014081}
}
Kostenlos starten →